-
Mashup Score: 0Artificial Intelligence in Cataract Surgery and Optometry at Large with Harvey Richman, OD, and Rebecca Wartman, OD - 2 hour(s) ago
Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.
Source: www.hcplive.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Skin of Color Savvy: UV Safety in Skin of Color, with Rebecca Vasquez, MD and Adewole Adamson, MD, MPP - 4 hour(s) ago
This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
A NEW Skin of Color Savvy🎙️ podcast is out today! This podcast, by @SkinOfColor and HCPLive, included Drs. Rebecca Vasquez (@UTSWDerm) & Adewole Adamson (@DellMedSchool). They discuss an important topic:☀️UV safety in skin of color. View here: https://t.co/cTkXrgIK7U https://t.co/5W9QlGygK9
-
-
Mashup Score: 0
Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Most patients with generalized pustules psoriasis did not achieve clear skin on small-molecule therapies, new EFFISAYIL®2 data show. #dermatology #SDPA2025 https://t.co/6bk6sBsyxG
-
-
Mashup Score: 0
Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
New data from the EFFISAYIL®2 trial show most patients with generalized pustular psoriasis (#GPP) didn’t achieve clear skin with small-molecule drugs. Targeted therapies like #spesolimab may offer better relief. #dermatology #SDPA2025 https://t.co/YH6tkb2mPS
-
-
Mashup Score: 0Kidney Compass: Sibeprenlimab and the VISIONARY Trial, with Vlado Perkovic, MBBS, PhD, at ERA 2025 - 7 hour(s) ago
Discover groundbreaking insights on the VISIONARY trial, IgA nephropathy treatment, and the future of kidney care with expert Vlado Perkovic, MBBS, PhD.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
ICYMI: This episode of #KidneyCompass offers a deep dive into sibeprenlimab, VISIONARY, and the latest in #IgAN. Learn more: https://t.co/pKTYDu8vLa https://t.co/7U3XsUEsSx
-
-
Mashup Score: 0Evolving Treatment Paradigms in Hypercortisolism: Integrating Emerging Evidence into Practice - 9 hour(s) ago
Richard Pratley, MD; Vivian Fonseca, MD, FRCP; Ralph DeFronzo, MD; Richard Auchus, MD, PhD; and Natalie Bellini, DNP, FNP, BC-ADM, CDCES, discuss how the groundbreaking CATALYST trial results revealed that approximately 25% of patients with difficult-to-control diabetes despite optimal medical management have hypercortisolism, representing a treatable cause of treatment-resistant diabetes that can be identified through simple dexamethasone suppression testing and managed with targeted therapies such as mifepristone or surgical intervention for adrenal adenomas.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
Drs. @RPratleyMD, Vivian Fonseca, Ralph DeFronzo, Richard Auchus, & @Natalie_Bellini explore how about 25% of patients with hard-to-control diabetes have hypercortisolism. Learn how a simple test and targeted treatments can make a difference. Watch Now: https://t.co/vk7fF6npWO https://t.co/b96B18Njyh
-
-
Mashup Score: 0
Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
J&J (@JNJNews) submits sNDA for #CAPLYTA (#lumateperone) to prevent #schizophrenia relapse. Phase 3 data show a 63% reduced risk of relapse vs placebo, with a consistent safety profile. #FDA review now underway. Read more about the submission here: https://t.co/WqOFq7zAq9
-
-
Mashup Score: 2Skin of Color Savvy: UV Safety in Skin of Color, with Rebecca Vasquez, MD and Adewole Adamson, MD, MPP - 12 hour(s) ago
This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
A NEW Skin of Color Savvy🎙️ podcast is out today! This podcast, by @SkinOfColor and HCPLive, included Drs. Rebecca Vasquez (@UTSWDerm) & Adewole Adamson (@DellMedSchool). They discuss an important topic:☀️UV safety in skin of color. View here: https://t.co/cTkXrgIK7U https://t.co/5W9QlGygK9
-
-
Mashup Score: 0
Veeral Sheth, MD, is joined by the director of marketing of eSight to discuss the 5th generation eSight Go, a device to enhance central vision functions in patients with a variety of eye diseases.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
In this episode, Veeral Sheth, MD (@URetina) and Roland Mattern (@eSightEyeware) discuss the promising new eSight Go visual correction device and how it can be implemented in the ophthalmic sphere! Watch now: https://t.co/05XwkLZNFF https://t.co/ebe0tjwelo
-
-
Mashup Score: 0Positive 16-Week Findings Highlighted on Tralokinumab for Atopic Dermatitis on the Hands - 13 hour(s) ago
These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.
Source: www.hcplive.comCategories: General Medicine NewsTweet-
🚨NEW🚨 A release by LEO Pharma on new phase 3b interim findings highlights a few key points, including... Tralokinumab (ADBRY) use led to significant improvements in hand-specific #AtopicDermatitis within 16 weeks during the ADHAND trial. View more: https://t.co/3u2qT8mCDc
-
At #AOA25, we sat down with Harvey Richman, OD, and Rebecca Wartman, OD, to discuss their presentation on #AI and its use in cataract surgery. Watch the full video here: https://t.co/5CRuwrhB03 https://t.co/82xj7VZWQ3